Category: Medicine and Healthcare

Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue
FEATURED
Press Release Feb 6, 2018
Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue

50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.
Royal Biologics Withdraws From the Alliance of Wound Care Stakeholders Over Support for Restrictive LCD Policies
Press Release Apr 4, 2025
Royal Biologics Withdraws From the Alliance of Wound Care Stakeholders Over Support for Restrictive LCD Policies

Royal Biologics Takes a Stand Against Policies That Limit Patient Access, Suppress Innovation, and Drive Up Healthcare Costs
Royal Wound-X to Launch and Showcase New Cutting-Edge Technologies at SAWC 2024
Press Release Oct 1, 2024
Royal Wound-X to Launch and Showcase New Cutting-Edge Technologies at SAWC 2024
Royal Wound-X Receives IRB Approval and Commences Randomized Controlled Trials for Pivotal Products
Press Release Sep 11, 2024
Royal Wound-X Receives IRB Approval and Commences Randomized Controlled Trials for Pivotal Products
Press Release Nov 28, 2023
Royal Biologics Announces Commerical Launch of Derm-Maxx™ and Newly Formed Wound Care Division
Press Release May 23, 2023
Royal Biologics Announces Licensing and U.S. Commercial Launch of Bio-Reign 3D (TM)
Press Release Feb 14, 2023
Royal Biologics Announces U.S. Commercial Launch of BIOINCYTE™ PRFM

BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet System
Royal Biologics Announces FDA 510K Approval and U.S. Commercial Launch of the MAXX™-BMC Bone Marrow Aspirate Concentration System
Press Release Jun 1, 2022
Royal Biologics Announces FDA 510K Approval and U.S. Commercial Launch of the MAXX™-BMC Bone Marrow Aspirate Concentration System
Press Release Feb 15, 2021
Royal Biologics Wound Care Portfolio Receives High-Tier Reimbursement

Royal Biologics' Cryo-Cord™, Amnio-Maxx™, Amnio-Maxx™ Lite and Derm-Maxx™ Receive High-Tier Reimbursement in the Hospital Outpatient Departments and Reimbursement in the Physician Office to Treat Chronic Non-Healing Wounds
Royal Biologics Announces the Launch of Fibri-Cell™, Live Cellular Cortical Fibers With Osteo-Spin™ Technology
Press Release Nov 10, 2020
Royal Biologics Announces the Launch of Fibri-Cell™, Live Cellular Cortical Fibers With Osteo-Spin™ Technology
Press Release Sep 29, 2020
Royal Biologics Completes 100th Cyro Cord™ Case, Successfully Enrolls First Patient Into Diabetic Foot Ulcer Study
Press Release Sep 1, 2020
Royal Biologics Announces the Acquisition of FIBRINET

The acquisition of the FIBRINET system adds new novel technology to Royal Biologics' growing portfolio of Autologous Live Cell solutions
Royal Biologics Launches MAXX™-Fuse
Press Release Feb 20, 2018
Royal Biologics Launches MAXX™-Fuse

Royal Biologics Launches MAXX™-Fuse, a demineralized bone matrix product derived from 100 percent human bone